Kevin W. Christensen

Kevin W. Christensen, PhD is a director in BRG’s Washington, DC office. Dr. Christensen specializes in antitrust and competition policy, public policy, and damages analysis, often applied in the context of the pharmaceutical industry.

He regularly works on class action litigation matters to address questions of class certification and estimation of classwide damages. He has submitted expert reports to the US District Court for the District of Columbia and regulatory agencies. He has provided deposition testimony in state court. Additionally, he has written white papers submitted to the State of Florida’s Department of Transportation and drafted portions of new product applications submitted to the US Food and Drug Administration (FDA).

Dr. Christensen has been involved in antitrust and competition matters that included price fixing, monopoly and attempted monopoly, monopsony and attempted monopsony, market allocation, raising rivals costs, and tying and bundling allegations. He also has worked on several mergers and acquisitions and nonpublic investigations by federal agencies. For economic regulation matters, Dr. Christensen has estimated the economic and tax revenue impact of proposed infrastructure investments or regulatory changes. Finally, he has estimated economic damages in a variety of antitrust and false advertising litigations and has provided testimony on economic damages resulting from bribery. His work spans oil and gas, pharmaceutical, biotechnology, medical device, banking, automobile finance, wholesale distribution, transportation, consumer packaged goods (CPG), agriculture, building materials, tourism, and gaming industries.